Tenax Therapeutics, Inc.
Symbol: TENX (NASDAQ)
6.06
▼ (-0.98%) -0.060
Company Description:
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Key Stats
- Today's Open: $6.1397
- Today's High: $6.295
- Today's Low: $6.05
- Today's Volume: 27.77K
- Yesterday Close: $6.12
- Yesterday High: $6.2177
- Yesterday Low: $6
- Yesterday Volume: 118.65K
- Last Min Volume: 5.06K
- Last Min High: $6.06
- Last Min Low: $6.056
- Last Min VWAP: $6.05766
Company Profile
- Name: Tenax Therapeutics, Inc.
- Website: https://www.tenaxthera.com
- Listed Date: 1995-02-01
- Location: CHAPEL HILL, NC
- Market Status: Active
- CIK Number: 0000034956
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $27.92M
- Round Lot: 100
- Outstanding Shares: 4.56M
- Asset Type: CS
RECENT FILINGS FOR TENX
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-07-03 | 4 | View |
| 2025-06-30 | SCHEDULE 13G | View |
| 2025-06-17 | 8-K | View |
| 2025-05-20 | 4 | View |
| 2025-05-20 | 4 | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-04-25 | ARS | View |
Latest News on TENX